European CHMP recommends approval of paediatric license extension for pembrolizumab (Keytruda)

The intended license extension is as monotherapy for patients aged 3 years and older with relapsed or refractory classical Hodgkin lymphoma who have failed autologous stem cell transplant (ASCT) or following at least two prior therapies when ASCT is not a treatment option.

Source:

European Medicines Agency